{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:12:06Z","timestamp":1775639526869,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40261-020-00949-9","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T07:38:12Z","timestamp":1595921892000},"page":"991-1000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus"],"prefix":"10.1007","volume":"40","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"issue":"7","key":"949_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.tem.2013.03.005","volume":"24","author":"SA Soleimanpour","year":"2013","unstructured":"Soleimanpour SA, Stoffers DA. The pancreatic B cell and type 1 diabetes: innocent bystander or active participant? Trends Endocrinol Metab. 2013;24(7):324\u201331.","journal-title":"Trends Endocrinol Metab."},{"issue":"1","key":"949_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4239\/wjd.v11.i1.13","volume":"11","author":"AM Giwa","year":"2020","unstructured":"Giwa AM, Ahmed R, Omidian Z, et al. Current understandings of the pathogenesis of type 1 diabetes: genetics to environment. World J Diabetes. 2020;11(1):13\u201325.","journal-title":"World J Diabetes."},{"issue":"3","key":"949_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4274\/jcrpe.3825","volume":"9","author":"\u015e Eray","year":"2017","unstructured":"Eray \u015e, U\u00e7ar HN, \u00c7etinkaya F, et al. The relationship between perceived family climate and glycemic control in type 1 diabetes mellitus adolescent patients. J Clin Res Pediatr Endocrinol. 2017;9(3):253\u20139.","journal-title":"J Clin Res Pediatr Endocrinol."},{"issue":"12","key":"949_CR4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1080\/1744666X.2018.1538787","volume":"14","author":"K Sharif","year":"2018","unstructured":"Sharif K, Watad A, Coplan L, et al. Psychological stress and type 1 diabetes mellitus: what is the link? Expert Rev Clin Immunol. 2018;14(12):1801\u20138.","journal-title":"Expert Rev Clin Immunol."},{"key":"949_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.gde.2018.03.009","volume":"50","author":"SA Sharp","year":"2018","unstructured":"Sharp SA, Weedon MN, Hagopian WA, et al. Clinical and research uses of genetic risk scores in type 1 diabetes. Curr Opin Genet Dev. 2018;50:96\u2013102.","journal-title":"Curr Opin Genet Dev."},{"issue":"7","key":"949_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034\u201354.","journal-title":"Diabetes Care."},{"issue":"12","key":"949_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.4239\/wjd.v10.i12.560","volume":"10","author":"N Gomez-Lopera","year":"2019","unstructured":"Gomez-Lopera N, Pineda-Trujillo N, Diaz-Valencia P. Correlating the global increase in type 1 diabetes incidence across age groups with national economic prosperity: a systematic review. World J Diabetes. 2019;10(12):560\u201380.","journal-title":"World J Diabetes."},{"issue":"1","key":"949_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11892-020-1290-7","volume":"20","author":"SA Barry-Menkhaus","year":"2020","unstructured":"Barry-Menkhaus SA, Wagner DV, Riley AR. Small interventions for big change: brief strategies for distress and self-management amongst youth with type 1 diabetes. Curr Diab Rep. 2020;20(1):3.","journal-title":"Curr Diab Rep."},{"issue":"2","key":"949_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/01612840590901590","volume":"26","author":"J Massengale","year":"2005","unstructured":"Massengale J. Depression and the adolescent with type 1 diabetes: the covert comorbidity. Issues Ment Health Nurs. 2005;26(2):137\u201348.","journal-title":"Issues Ment Health Nurs."},{"issue":"1","key":"949_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.diabres.2015.04.010","volume":"109","author":"S Alemu","year":"2015","unstructured":"Alemu S, Dessie A, Tsegaw A, et al. Retinopathy in type 1 diabetes mellitus: major differences between rural and urban dwellers in northwest Ethiopia. Diabetes Res Clin Pract. 2015;109(1):191\u20138.","journal-title":"Diabetes Res Clin Pract."},{"key":"949_CR11","doi-asserted-by":"publisher","first-page":"6425359","DOI":"10.1155\/2017\/6425359","volume":"2017","author":"M Vladu","year":"2017","unstructured":"Vladu M, Clenciu D, Efrem IC, et al. Insulin resistance and chronic kidney disease in patients with type 1 diabetes mellitus. J Nutr Metab. 2017;2017:6425359.","journal-title":"J Nutr Metab."},{"issue":"11","key":"949_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00592-019-01384-9","volume":"56","author":"M Trento","year":"2019","unstructured":"Trento M, Charrier L, Cavallo F, et al. Vision-related quality of life and locus of control in type 1 diabetes: a multicenter observational study. Acta Diabetol. 2019;56(11):1209\u201316.","journal-title":"Acta Diabetol."},{"issue":"2","key":"949_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4158\/EP15869.RA","volume":"22","author":"BW Bode","year":"2016","unstructured":"Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract. 2016;22(2):220\u201330.","journal-title":"Endocr Pract."},{"issue":"4","key":"949_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"MA Hediger","year":"1994","unstructured":"Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. 1994;74(4):993\u20131026.","journal-title":"Physiol Rev."},{"issue":"1","key":"949_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27\u201338.","journal-title":"Cell Metab."},{"issue":"14","key":"949_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40265-017-0801-6","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED, Scheen AJ. Canagliflozin: a review in type 2 diabetes. Drugs. 2017;77(14):1577\u201392.","journal-title":"Drugs."},{"key":"949_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2147\/TCRM.S137068","volume":"14","author":"G Derosa","year":"2018","unstructured":"Derosa G, Maffioli P. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. Ther Clin Risk Manag. 2018;14:1637\u201340.","journal-title":"Ther Clin Risk Manag."},{"issue":"3","key":"949_CR18","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.dsx.2019.04.035","volume":"13","author":"G Chawla","year":"2019","unstructured":"Chawla G, Chaudhary KK. A complete review of empagliflozin: most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(3):2001\u20138.","journal-title":"Diabetes Metab Syndr."},{"issue":"10","key":"949_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346.","journal-title":"Drugs."},{"issue":"7","key":"949_CR20","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/dom.14011","volume":"22","author":"HS Bajaj","year":"2020","unstructured":"Bajaj HS, Raz I, Mosenzon O, et al. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020;22(7):1122\u201331.","journal-title":"Diabetes Obes Metab."},{"issue":"21","key":"949_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"New Engl J Med."},{"issue":"2","key":"949_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1479164114563304","volume":"12","author":"P Lapuerta","year":"2015","unstructured":"Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor. Diab Vasc Dis Res. 2015;12(2):101\u201310.","journal-title":"Diab Vasc Dis Res."},{"key":"949_CR23","unstructured":"European Medicines Agency. Forxiga: EPAR: medicine overview. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga-epar-medicine-overview_en.pdf. Accessed 11 Mar 2020."},{"key":"949_CR24","unstructured":"European Medicines Agency. Zynquista 200 mg flm-coated tablets: summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zynquista-epar-medicine-overview_en.pdf. Accessed 11 Mar 2020."},{"issue":"10","key":"949_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S2213-8587(19)30265-7","volume":"7","author":"AI Adler","year":"2019","unstructured":"Adler AI, Ting S, Dent R, et al. NICE guidance on dapagliflozin with insulin for type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(10):750\u20131.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"949_CR26","unstructured":"AstraZeneca. Update on US regulatory decision for Farxiga in type-1 diabetes. 2019. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2019\/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html. Accessed 11 Mar 2020."},{"key":"949_CR27","unstructured":"Sanofi. Sanofi: FDA issues complete response letter for Zynquista\u2122 (sotagliflozin). 2019. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-03-22-19-15-00. Accessed 11 Mar 2020."},{"key":"949_CR28","unstructured":"Company ELa. US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes. 2020. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/us-fda-issues-complete-response-letter-empagliflozin-25-mg. Accessed 11 Mar 2020."},{"issue":"3","key":"949_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/dom.12594","volume":"18","author":"W Tang","year":"2016","unstructured":"Tang W, Leil TA, Johnsson E, et al. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(3):236\u201340.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"949_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc13-2955","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412\u20139.","journal-title":"Diabetes Care."},{"issue":"11","key":"949_CR31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/dom.12975","volume":"19","author":"T Biester","year":"2017","unstructured":"Biester T, Aschemeier B, Fath M, et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and \u00df-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab. 2017;19(11):1635\u20139.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"949_CR32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/dom.13593","volume":"21","author":"H Watada","year":"2019","unstructured":"Watada H, Shiramoto M, Ueda S, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes Obes Metab. 2019;21(4):876\u201382.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"949_CR33","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bcp.13981","volume":"85","author":"D Busse","year":"2019","unstructured":"Busse D, Tang W, Scheerer MF, et al. Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent\/young adult and adult patients with type 1 diabetes mellitus. Br J Clin Pharmacol. 2019;85(8):1820\u20138.","journal-title":"Br J Clin Pharmacol."},{"key":"949_CR34","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:864\u201376.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"949_CR35","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938\u201346.","journal-title":"Diabetes Care."},{"issue":"6","key":"949_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2337\/dc18-1983","volume":"42","author":"C Mathieu","year":"2019","unstructured":"Mathieu C, Dandona P, Phillip M, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: Pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081\u20139.","journal-title":"Diabetes Care."},{"issue":"12","key":"949_CR37","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"P Dandona","year":"2018","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552\u20139.","journal-title":"Diabetes Care."},{"key":"949_CR38","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s40265-019-01213-x","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Blair HA. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019;79:1877\u201384.","journal-title":"Drugs."},{"issue":"4","key":"949_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/dom.13922","volume":"22","author":"E Araki","year":"2020","unstructured":"Araki E, Watada H, Uchigata Y, et al. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. Diabetes Obes Metab. 2020;22(4):540\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"949_CR40","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560\u20139.","journal-title":"Diabetes Care."},{"issue":"24","key":"949_CR41","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. New Engl J Med. 2017;377(24):2337\u201348.","journal-title":"New Engl J Med."},{"issue":"9","key":"949_CR42","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","volume":"41","author":"JB Buse","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American Intandem1 study. Diabetes Care. 2018;41(9):1970\u201380.","journal-title":"Diabetes Care."},{"issue":"9","key":"949_CR43","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2337\/dc18-0342","volume":"41","author":"T Danne","year":"2018","unstructured":"Danne T, Cariou B, Banks P, et al. Hba1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European Intandem2 study. Diabetes Care. 2018;41(9):1981\u201390.","journal-title":"Diabetes Care."},{"issue":"4","key":"949_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2019;380(4):347\u201357.","journal-title":"New Engl J Med."},{"key":"949_CR45","doi-asserted-by":"publisher","first-page":"I1328","DOI":"10.1136\/bmj.l1328","volume":"365","author":"G Musso","year":"2019","unstructured":"Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019;365:I1328.","journal-title":"BMJ."},{"issue":"7","key":"949_CR46","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/dom.13992","volume":"22","author":"H Bennett","year":"2020","unstructured":"Bennett H, Tank A, Evans M, et al. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes Obes Metab. 2020;22(7):1047\u201355.","journal-title":"Diabetes Obes Metab."},{"key":"949_CR47","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.2147\/DMSO.S190356","volume":"12","author":"I Avgerinos","year":"2019","unstructured":"Avgerinos I, Liakos A, Tsapas A, et al. Cardiovascular risk reduction in type 2 diabetes: therapeutic potential of dapagliflozin. Diabetes Metab Syndr Obes. 2019;12:2549\u201357.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"10","key":"949_CR48","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.2337\/dc19-1177","volume":"42","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Shimabukuro M, Machii N, et al. Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: Results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care. 2019;42(10):e159\u201361.","journal-title":"Diabetes Care."},{"issue":"4","key":"949_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000506533","volume":"51","author":"MR Weira","year":"2020","unstructured":"Weira MR, McCullough PA, Buse JB, et al. Renal and cardiovascular effects of sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease: perspectives on the canagliflozin and renal events in diabetes with established nephropathy clinical evaluation trial results. Am J Nephrol. 2020;51(4):276\u201388.","journal-title":"Am J Nephrol."},{"key":"949_CR50","unstructured":"Edelman S, Jendle J, Dandona P, et al. Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes [abstract no. TH-PO1156 plus poster]. ASN Kidney Week; 2018, San Diego (CA)."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00949-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:17:32Z","timestamp":1650536252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00949-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00949-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"28 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}